BridgeMD
How does the antibiotic cefadroxil work in treating serious Staph infections? A first look
EU CTIS ID: 2025-522547-17-00
What this study is testing
To understand how the body processes and responds to the antibiotic cefadroxil by patients with a bloodstream infection caused by Staphylococcus aureus
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adults aged 18 years and older
- Ability to provide informed consent
- Diagnose of SAB based on clinical (sign of any infections) and microbiological (blood cultures posi-tive for Staphylococcus aureus) criteria.
- Clinical Improvement on initial intravenous antibiotic
- At least one set of negative blood cultures - No signs of persistent bacteremia
- Oral Tolerance - Ability to swallow and absorb oral medication - No suspicion of malabsorption
You likely can't join if
- Persistent bacteremia at inclusion time-point
- Pregnancy or breastfeeding
- Inability to receive oral medication or suspicion of malabsorption (gastrectomy or similar GI resec-tion / operation)
- Allergy to beta-lactams or cephalosporin
- In case of endocarditis, severe drug-drug interactions with Rifampin.
- Patients should be randomized within 7 days from first negative blood culture
See the full eligibility criteria
- Adults aged 18 years and older
- Ability to provide informed consent
- Diagnose of SAB based on clinical (sign of any infections) and microbiological (blood cultures posi-tive for Staphylococcus aureus) criteria.
- Clinical Improvement on initial intravenous antibiotic
- At least one set of negative blood cultures - No signs of persistent bacteremia
- Oral Tolerance - Ability to swallow and absorb oral medication - No suspicion of malabsorption
- Timing - ≤ 7 days of first negative blood culture
- Persistent bacteremia at inclusion time-point
- Pregnancy or breastfeeding
- Inability to receive oral medication or suspicion of malabsorption (gastrectomy or similar GI resec-tion / operation)
- Allergy to beta-lactams or cephalosporin
- In case of endocarditis, severe drug-drug interactions with Rifampin.
- Patients should be randomized within 7 days from first negative blood culture
- Polymicrobial infection
- Staphylococcus aureus infection by an isolate which is not susceptible to cefadroxil
- Hemodynamically instability at inclusion time point (systolic blood pressure < 100/mmHg, serum lactate> 2mmol/L; patient under noradrenaline drip)
- Source control: In case of deep routed infection/prothesis infection and surgery indication, no performance of surgical source control due to patient’ health status or preferences. In case of catheter or intravascular device infections this should be removed before inclusion.
- BMI > 40kg/m2
- eGFR > 130ml/min or eGFR <25ml/min
- Severe immunocompromised state (neutropenia (<500 neutrophils/μl); immunosuppressive combina-tion therapy with two or more drugs with different mode of action or biological therapy; solid organ transplantation; hematopoietic stem cell transplantation)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.